CatalYm GmbH’s Post

Discover the benefits of working with a specialty oncology CRO, like Catalyst Oncology. We understand the growing complexity of oncology drug development and offer deep oncology expertise throughout each function. Our nimble processes, industry-leading technologies, and quality site relationships set us apart from large generalist CROs.    We’re proud to be exclusively biotech, serving the best interests of biotech sponsors. Let’s transform the future of oncology together. Read more: https://lnkd.in/egvf528u #ConnectWithCatalyst #Oncology #OncologyResearch #Biotech #ClinicalTrials #DrugDevelopment #Oncology #ASCO2024

Discover the benefits of working with a specialty oncology CRO, like Catalyst Oncology. We understand the growing complexity of oncology drug development and offer deep oncology expertise throughout each function. Our nimble processes, industry-leading technologies, and quality site relationships set us apart from large generalist CROs.    We’re proud to be exclusively biotech, serving the best interests of biotech sponsors. Let’s transform the future of oncology together. Read more: https://lnkd.in/egvf528u #ConnectWithCatalyst #Oncology #OncologyResearch #Biotech #ClinicalTrials #DrugDevelopment #Oncology #ASCO2024

Great news! We’re back with part two of our report on Digital Therapeutics in Oncology.   Part 1, Advancing Outcomes Design, focused on the clinical perspective. In this second part, my colleagues Geoff McCleary, Sameera Singh, and I take a deep dive into the evaluation criteria for DTx solutions in oncology.   Join us as we critically dissect the trifecta of innovation and summarize innovation models. We outline the three key considerations for emerging partnerships between pharma and digital health start-ups: Desirability, Feasibility, and Viability.   🔗 Download and read our new report: Digital Therapeutics in Oncology: Innovation Models https://lnkd.in/etkGANe9   #DigitalHealth #Oncology #FutureOfHealthcare #CapgeminiInvent    Damien Vossion Gwenael Dorval Barnabé Lecouteux Yousra Tourki Nicolas Artzimovitch Aéthalie Chabriol Igal Slama Salah AZIZI Cyril Francois  

Based on our estimates in Oncology Drug Discovery, approximately 11% of the data from the previous year is completely abandoned, while 18-20% new information is added each year. This results in a 28-30% change annually, meaning that every third year, you’re working with an entirely fresh set of intelligence. For instance, in 2024 alone, we removed over 300 oncology drug developers and nearly 400 molecules from our main database compared to 2023. At the same time, we added 425 new companies and moved more than 150 companies from preclinical to clinical stages, ensuring our data remains actionable and valuable to our users. Data on abandoned oncology drug developers is available upon request at reports@omicsx.com. #oncology #cancer

At TD2, we understand that accelerating cancer therapies from concept to clinic requires a robust, integrated approach. That's why we've developed our Comprehensive Oncology Ecosystem, designed to streamline and optimize every step of your drug development journey. https://hubs.li/Q02NrDTv0 Our ecosystem is more than just a service offering—it's a dynamic, end-to-end platform that combines cutting-edge science, state-of-the-art technology, and unmatched expertise. From preclinical evaluation using innovative models to clinical trials and regulatory support, our team is here to drive your oncology program forward with precision and efficiency. 🌟 Why Partner with TD2? ~Integrated Capabilities: Seamlessly transition from preclinical to clinical phases with our fully connected services. ~Expert Team: Collaborate with leading scientists, clinicians, and regulatory experts dedicated to oncology. ~Accelerated Timelines: Reduce time to market with our streamlined processes and comprehensive support. #OncologyResearch #CancerTherapies #DrugDevelopment #ClinicalTrials #OncologyEcosystem #TD2